Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment
- 17 Downloads
Inhibition of monoamine oxidase (MAO)-A/B can ameliorate depressive- and anxiety-related symptoms via increase of monoamine extracellular levels. However, such inhibition can also instigate hypertensive response following exposure to dietary tyramine (i.e., “the cheese effect”). Novel herbal treatment (NHT) is an herbal formula that has been demonstrated to reduce depressive- and anxiety-like symptoms in pre-clinical studies. The aim of the current study was to examine whether the therapeutic potential of NHT is underlain by inhibition of MAO-A/B and whether NHT poses a risk for tyramine hyper-potentiation. Unpredictable chronic mild stress (UCMS)–exposed mice and naïve mice were treated for 3 weeks with NHT (30 mg/kg; i.p.), the selective serotonin reuptake inhibitor (SSRI) escitalopram (15 mg/kg; i.p.), or saline. Subsequently, MAO-A/B activities in the hypothalamus, striatum, and prefrontal cortex (PFC) were assessed. Exposure to UCMS led to significant increases in both MAO-A and MAO-B activities in the hypothalamus (p < 0.001) and in the PFC (p < 0.01 for MAO-A; p < 0.001 for MAO-B). Neither NHT nor escitalopram had any notable effects. Treatment with NHT was supported as safe in terms of risk for inducing a hypertensive response. The antidepressant- and anxiolytic-like effects of NHT are mediated via pathways other than MAO-A/B inhibition.
KeywordsMonoamine oxidase A/B (MAO-A/B) Unpredictable chronic mild stress (UCMS) Depression Novel herbal treatment (NHT) Escitalopram
The authors would like to thank Nadav Kately for inventing and developing the NHT formula, Yafit Hirshler for her support in the realization of the manuscript, and Dr. Fong-pin Liang from KPC for his support in gathering data regarding the herbal compounds of NHT used in this study.
Compliance with Ethical Standards
All procedures were performed in accordance with the ethical standards of The Academic College Tel Aviv Yaffo Committee for Animal Care and Use, and The Guide for the Care and Use of Laboratory Animals of the National Institutes of Health guidelines were followed.
Conflict of Interest
Ravid Doron has an approved patent relating to the herbal treatment for anxiety disorders (patent no. 9,320,772, USA). Other than that, all authors assert that none has any commercial or financial involvements that might present an appearance of a conflict of interest in connection with the submitted manuscript.
- Aluf Y, Vaya J, Khatib S, Loboda Y, Finberg JPM (2013) Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. Neuropharmacology. 65:48–57. https://doi.org/10.1016/j.neuropharm.2012.08.023 CrossRefGoogle Scholar
- Burstein O, Doron R (2018) The unpredictable chronic mild stress protocol for inducing anhedonia in mice. J Vis Exp. https://doi.org/10.3791/58184
- Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan S, Shamir A, Toledano R, Simhon O, Hirshler Y, Chen G, Doron R (2017) Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS One 12. https://doi.org/10.1371/journal.pone.0188043
- Davidson JRT (2010) Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 71. https://doi.org/10.4088/JCP.9058se1c.04gry
- Doron R, Lotan D, Versano Z, Benatav L, Franko M, Armoza S, Kately N, Rehavi M (2014b) Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications. PLoS One 9. https://doi.org/10.1371/journal.pone.0091455
- Fagervall I, Ross SB (1986) A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. J Neurochem 47:569–576. https://doi.org/10.1111/j.1471-4159.1986.tb04537.x CrossRefGoogle Scholar
- Finberg JPM, Gillman K (2011) Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 100:169–190. https://doi.org/10.1016/B978-0-12-386467-3.00009-1 CrossRefGoogle Scholar
- Kato T, Dong B, Ishii K, Kinemuchi H (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J Neurochem 46:1277–1282. https://doi.org/10.1111/j.1471-4159.1986.tb00650.x CrossRefGoogle Scholar
- Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song WY, Kennedy SH, MacQueen GM, Milev RV, Parikh SV, Ravindran AV, the CANMAT Depression Work Group (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatr 61:510–523. https://doi.org/10.1177/0706743716659416 CrossRefGoogle Scholar
- Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (2006) Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63:1209. https://doi.org/10.1001/archpsyc.63.11.1209 CrossRefGoogle Scholar
- Scheid V, Bensky D, Ellis A, Barolet R (2009) Chinese herbal medicine: formulas and strategies, 2nd edn. Eastland Press, WA, USAGoogle Scholar
- Shioda K, Nisijima K, Yoshino T, Kato S (2004) Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuro-Psychopharmacology Biol Psychiatry 28:633–640. https://doi.org/10.1016/j.pnpbp.2004.01.013 CrossRefGoogle Scholar
- Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66:974–981. https://doi.org/10.4088/JCP.v66n0803 CrossRefGoogle Scholar
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40. https://doi.org/10.1176/appi.ajp.163.1.28 CrossRefGoogle Scholar
- Wachtel SR, Abercrombie ED (1994) L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63:108–117. https://doi.org/10.1046/j.1471-4159.1994.63010108.x CrossRefGoogle Scholar
- Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJL, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586. https://doi.org/10.1016/S0140-6736(13)61611-6 CrossRefGoogle Scholar
- World Health Organization (2003) WHO guidelines on good agricultural and collection practices (GACP) for medicinal plantsGoogle Scholar
- World Health Organization (2017) Depression and other common mental disordersGoogle Scholar